Terminated PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT05860296

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

An Open-Label, Phase 1b/2a Study of SLC-391, an AXL Inhibitor, in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Merck Sharp & Dohme LLC

Conditions Lung Cancer Metastatic Lung Cancer Stage IV Lung Cancer, Nonsmall Cell

Interventions SLC-391 pembrolizumab

Updated 15 times since 2023 Last updated: Dec 16, 2025 Started: May 31, 2023 Primary completion: Dec 1, 2025 Completion: Dec 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of efficacy and enrollment challenges

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

This PHASE1/PHASE2 trial investigates Lung Cancer Metastatic and Lung Cancer Stage IV and is currently terminated or withdrawn. Merck Sharp & Dohme LLC leads this study, which shows 15 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

15 versions recorded

Jan 2026 — Present [monthly]

Terminated PHASE1/PHASE2

Status: Recruiting → Terminated
Sep 2025 — Jan 2026 [monthly]

Recruiting PHASE1/PHASE2
Dec 2024 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 10 earlier versions

May 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Mar 2024 — May 2024 [monthly]

Recruiting PHASE1_PHASE2
Jan 2024 — Mar 2024 [monthly]

Recruiting PHASE1_PHASE2
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE1_PHASE2
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE1_PHASE2
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE1_PHASE2
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE1_PHASE2
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE1_PHASE2
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2023 — Jul 2023 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

May 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
SignalChem Lifesciences Corporation

Data source: SignalChem Lifesciences Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Cleveland, United States , Detroit, United States , Edmonton, Canada , Hamilton, Canada , Indianapolis, United States , Lafayette, United States , London, Canada , Montreal, Canada , Oklahoma City, United States , Omaha, United States and 1 more location